GSK - GSK plc
NEXT EARNINGS:
Apr 29, 2026
EPS Est: $1.18
|
Rev Est: $7.6B
Price:
--
--
|
CONSENSUS:
Hold
DETAILS
Market Cap:
119.25B
Volume:
5,717,217
Avg Volume:
4,901,691
52 Week Range:
32.38-61.7
Sector:
Healthcare
Industry:
Drug Manufacturers - General
Beta:
0.27
Last Dividend:
$1.76
Exchange:
NYSE
Country:
GB
Employees:
68,629
IPO Date:
1980-03-28
EPS (TTM):
2.76
P/E Ratio:
21.39
Revenue (TTM):
31.95B
Total Assets:
61.01B
Total Debt:
17.69B
Cash & Equiv:
3.39B
Rev Growth (5Y):
-1.5%
EPS Growth (5Y):
-11.6%
FCF Growth (5Y):
-9.4%
ROCE:
20.0%
Debt/Equity:
1.24
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2026-02-04 | $0.68 | $0.64 | +6.3% | $8.5B | $7.7B | +10.2% |
| 2025-10-29 | $1.48 | $1.26 | +17.5% | $8.5B | $8.5B | +0.8% |
| 2025-07-30 | $0.96 | — | — | $10.9B | — | — |
| 2025-04-30 | $1.13 | $1.08 | +4.6% | $9.7B | $7.9B | +22.1% |
| 2025-02-05 | $0.59 | $0.44 | +34.1% | $10.2B | $9.5B | +6.5% |
| 2024-10-30 | $1.27 | $1.16 | +9.5% | $10.5B | $10.1B | +3.9% |
| 2024-07-31 | $1.09 | $1.00 | +9.0% | $10.0B | $9.7B | +3.3% |
| 2024-01-31 | $0.72 | $0.76 | -5.3% | $9.2B | $9.7B | -4.4% |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 31.95B | 31.38B | 30.33B | 29.32B | 24.70B | 24.35B | 33.75B | 30.82B | 30.19B | 27.89B | 23.92B | 23.01B |
| Net Income | 5.59B | 2.58B | 4.93B | 14.96B | 4.38B | 5.75B | 4.64B | 3.62B | 1.53B | 912.00M | 8.42B | 2.76B |
| EPS | 2.76 | 1.26 | 2.44 | 2.44 | 2.74 | 2.88 | 2.34 | 1.84 | 0.78 | 0.48 | 4.36 | 1.44 |
| Total Assets | 61.01B | 59.46B | 75.22B | 60.15B | 107.14B | 109.95B | 105.57B | 58.07B | 56.38B | 59.08B | 53.45B | 40.65B |
| Total Debt | 17.69B | 16.99B | 22.97B | 20.99B | 32.74B | 37.11B | 40.42B | 26.06B | 17.09B | 18.79B | 16.63B | 18.78B |
| Cash & Equivalents | 3.39B | 3.69B | 3.74B | 3.72B | 5.79B | 8.60B | 6.24B | 3.87B | 3.83B | 4.90B | 5.83B | 4.34B |
| Operating Cash Flow | 7.14B | 6.55B | 7.89B | 8.16B | 7.95B | 8.44B | 8.02B | 8.42B | 6.92B | 6.50B | 2.57B | 5.18B |
| Free Cash Flow | 5.82B | 3.57B | 6.26B | 6.75B | 5.30B | 6.50B | 5.86B | 6.62B | 4.72B | 4.14B | 668.00M | 3.42B |
| FCF per Share | 2.88 | 1.75 | 3.09 | 3.35 | 3.31 | 3.26 | 2.96 | 3.37 | 2.41 | 2.13 | 0.35 | 1.78 |
| Book Value | 16.35B | 13.67B | 17.01B | 10.60B | 20.39B | 19.94B | 15.11B | 4.36B | (68.00M) | 1.12B | 5.11B | 4.26B |
| Cash & ST Investments | 3.40B | 3.71B | 6.61B | 7.88B | 5.87B | 8.71B | 6.34B | 3.96B | 3.91B | 4.99B | 5.91B | 4.41B |
| ROC Equity | 0.34 | 0.19 | 0.29 | 1.41 | 0.22 | 0.29 | 0.31 | 0.83 | N/A | 0.81 | 1.65 | 0.65 |